Patients with left ventricular assist devices (LVADs) are at high risk of sustained ventricular arrhythmias, but these may be remarkably well tolerated and the association with sudden death is unclear. Many patients who receive an LVAD already have an implantable cardioverter defibrillator (ICD). While it is standard practice to reactivate a previously implanted ICD in an LVAD recipient, this should include discussion of the revised risks and benefits of ICD therapy following LVAD implantation. In particular, patients should be warned that they might receive a significant number of ICD shocks that may not be life saving. When ICDs are reactivated, device programming should minimize the risk of repeated shocks for non-sustained or well-tolerated ventricular arrhythmias. Implantation of a primary prevention ICD after implantation of an LVAD is not supported by current evidence, poses potential risks, and should be the subject of a clinical trial before it becomes standard practice.
A patient with chronic heart failure and severe left ventricular (LV) systolic dysfunction caused by coronary artery disease received a HeartMate II left ventricular assist device (LVAD) as a bridge to transplantation. A primary prevention implantable cardioverter defibrillator (ICD) had been implanted 8 months prior to the LVAD. He has never required antitachycardia pacing (ATP) or shock therapy. These functions were deactivated before surgery. Should the ICD be reactivated after LVAD implantation and, if so, how should the ICD be programmed?
Are patients with left ventricular assist devices at risk of ventricular arrhythmias?
Ventricular tachycardia (VT) and ventricular fibrillation (VF) are common in patients with LVADs; case series, clinical trial data, and registry data are summarized in Table 1 . 1 -12 Comparison is limited by considerable variation in the definition of VT/VF. Most studies are small (only two include . 150 individuals) and the duration of follow-up is short. In the largest study, the Interagency Registry for Mechanical Circulatory Support (INTERMACS), cardiac arrhythmias were the third most common adverse event in LVAD patients (0.9 events per patient-year), after infection (2.1 events per patient-year) and bleeding (2.0 events per patientyear). 10 The risk of VT/VF is greatest in the early post-operative period. In the HeartMate II registry; the incidence of VT/VF was 10-fold higher in the first 30 days after LVAD implantation (1.89 events per patient-year) compared with subsequent follow-up (0.19 events per patient-year). 9 Similar findings were seen in two case series. 4, 7 In the HeartMate II trial, arrhythmias were less common with continuous-flow devices (0.69 events per patient year) than pulsatile-flow devices (1.31 events per patient-year). 8 What causes ventricular arrhythmias in left ventricular assist device patients? In 61 patients with a continuous-flow LVAD who received ICD therapy, 52% had monomorphic VT, 13% had polymorphic VT, and 35% had VF. 13 The VT/VF may be attributable to the underlying cardiac pathology or the LVAD itself. Placement of the LVAD inflow cannula at the LV apex may create a re-entrant circuit for VT. Suction events, due to acute LV underfilling or high pump speed, may be arrhythmogenic.
14 Acute unloading of the LV after LVAD implantation may prolong the QT interval, increasing the risk of postoperative VT/VF. 15 At a cellular level, LVAD support is associated with changes in the beta-adrenergic system and calcium handling which may alter the risk of VT/VF. 16 The relative importance of these mechanisms is uncertain; the high incidence of early postoperative VT/VF could suggest a transient proarrhythmic effect of surgery or a longer term antiarrhythmic effect of LVAD support. Randomized data from the HeartMate trial suggests that long-term LVAD support may be antiarrhythmic; a pulsatile-flow LVAD reduced the incidence of VT/VF compared with medical therapy [rate ratio 0.45, 95% confidence interval (CI) 0.22-0.90].
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What are the consequences of ventricular arrhythmias in left ventricular assist device patients?
Ventricular arrhythmias may have life-threatening haemodynamic consequences in patients with LVADs. In a series of 42 patients over 24 months with an unspecified type of LVAD, five patients experienced syncope during VT and one patient died of shockrefractory VF. 6 In a series of 23 patients supported with a continuous-flow LVAD for a mean of 341 days, three patients experienced haemodynamic compromise during VT/VF. 7 Three studies have reported an association between VT/VF during LVAD support and increased mortality, although this does not indicate a causal relationship. 4, 5, 12 In contrast, there are reports of LVAD patients who tolerate VT/VF remarkably well. In nine patients with a pulsatile-flow LVAD, VT/VF lasting up to 12 days caused weakness and palpitations but no syncope. There was a reduction in device flow, but no thrombo-embolic events or end-organ dysfunction. 2 In 32 patients with a pulsatile-flow LVAD, laboratory markers of inadequate systemic perfusion or right-sided heart failure were unchanged after termination of VT/VF. 4 In a remarkable case report, a 24-year-old female with a pulsatile-flow LVAD was in sustained VF for 15 months before cardiac transplantation. 17 Despite concern that continuous-flow LVADs may be less effective at supporting circulation in patients without an intrinsic rhythm, HeartMate II LVADs have supported a patient in VF for 12 h before defibrillation 18 and a patient in asystole for 2 months before cardiac transplantation. 19 In such cases, a low pulmonary vascular resistance is thought to be necessary to allow a Fontan-like circulation. Clinical trial data suggest that sudden arrhythmic death in LVAD patients is rare. In REMATCH, there were 41 deaths in the LVAD group. The incidence of fatal VT/VF was not detailed, although 37 of 41 deaths were clearly attributable to a non-arrhythmic cause. 3 Similar findings were reported in the HeartMate II registry. There were 56 deaths during LVAD support in 18 months of follow-up, of which 50 deaths were clearly attributable to a non-arrhythmic cause. 9 Importantly, these trials do not describe the extent to which patients may have been protected from sudden death by an ICD.
How many patients with left ventricular assist devices have an implantable cardioverter defibrillator?
LVAD support may be used as a bridge to recovery, a bridge to transplantation, or destination therapy in patients with severe heart failure, impending cardiogenic shock, and/or multiorgan failure. 20 Many of these patients have longstanding chronic heart failure and have previously received an ICD for primary or secondary prevention, leading to a significant overlap in device use. The burden of ICD therapy has been described in six series of LVAD patients ( This critical question has not been addressed in a prospective, randomized controlled trial. Limited observational data are available. Two studies suggest that a pre-existing ICD may confer a survival benefit after LVAD implantation. An ICD was associated with increased survival in a multivariable analysis of 144 LVAD patients, 45 of whom had an ICD (odds ratio 2.72, 95% CI 1.03-7.16; P ¼ 0.04). 23 In a similar study that included both a multivariable and a propensity-matched analysis, an ICD was associated with lower allcause mortality in 478 VAD patients, 90 of whom had an ICD (hazard ratio 0.55, 95% CI 0.32-0.94; P ¼ 0.028). 24 However, this study combined patients with left, right, and biventricular assist devices despite potentially important differences in their ability to support patients without an intrinsic rhythm. Both studies are susceptible to selection bias; ICDs may be more likely to be implanted in subjects with a better prognosis.
What are the risks of implantable cardioverter defibrillator use in patients with left ventricular assist devices?
Adverse effects with ICDs have been reported in three series of consecutive LVAD patients. In a series of 15 patients with a VentrAssist LVAD and a pre-existing ICD, LVAD placement caused a significant increase in right ventricular (RV) stimulation threshold and a reduction in R-wave sensing, but no VT/VF undersensing. The need for ICD revision was not described. During follow-up, two patients had shock-refractory VT/VF due to high defibrillation thresholds and one patient had an inappropriate shock due to electromagnetic interference. 25 In a series of 61 patients with a HeartMate II or Heartware LVAD, 14 (23%) patients required ICD revision for problems including loss of ICD telemetry (n ¼ 4), ICD generator depletion (n ¼ 4), RV lead failure (n ¼ 3), and haematoma (n ¼ 3). 13 In a series of 76 patients with several types of LVAD, two patients required ICD revision for loss of telemetry after implantation of a HeartMate II LVAD and six patients were hospitalized for ICD-related problems including generator depletion (n ¼ 4) and haematoma (n ¼ 2). 11 Loss of telemetry appears to be confined to ICDs which use an 8 kHz operating frequency, close to the 7.2 kHz frequency of the HeartMate II pulse width modulator; details of this interaction are described on the manufacturer's website. 26 ICD revision procedures are associated with a risk of infection. 27 This is a particular concern for LVAD patients, for whom system infection represents one of the most frequent and serious complications. 9 The incidence of infection in LVAD patients after ICD revision has not been described in the published case series.
Should primary prevention implantable cardioverter defibrillators be implanted in left ventricular assist device patients?
Patients with an LVAD were not represented in randomized controlled trials of primary prevention ICDs. No study has prospectively investigated whether or not patients who do not have an ICD before LVAD implantation should have an ICD implanted subsequently. Implantation of a primary prevention ICD after LVAD implantation is not addressed by European Society of Cardiology guidelines on device use. 28 Any potential benefit must be balanced against the uncertain risk of complications. Infection is a particular concern and could be a catastrophic in LVAD patients. We believe that the risk -benefit ratio should be examined in a prospective, randomized controlled trial before implantation of primary prevention ICDs can be recommended after LVAD implantation.
How should implantable cardioverter defibrillators be programmed in left ventricular assist device patients?
Where an ICD is already in situ, there is little evidence to guide programming after LVAD implantation. Most ICDs detect VT/VF and deliver shock therapy before loss of consciousness. Consequently, ICD shocks are painful and associated with reduced quality of life. 29 LVAD patients may have a high burden of non-sustained VT, especially in the early post-operative period. Sustained VT/VF may be well tolerated, at least in the short term, and refractory to ICD therapy. Frequent ICD shocks will contribute to premature generator depletion. One group suggested that LVAD patients who develop VT/VF should be assessed for haemodynamic compromise and those with decreased LVAD flow or acute right heart failure should be treated with cardioversion. 4 This approach is incompatible with an ICD that will make decisions solely on the basis of heart rate and supraventricular tachycardia discriminators. Two groups have reported ICD programming in their LVAD patients; one used standard programming and one used long detection periods of 10 s for VT and 3 s for VF to reduce the chance of ICD therapy for non-sustained VT. 11, 13 Longer detection periods reduced ICD shocks without altering clinical outcome in two trials of ICD programming for patients that did not have LVADs. 30, 31 However, these detection periods are still shorter than the programmable maximum for many ICDs.
We believe that ICD therapy should be tailored to individual patients. We considered electrophysiological (EP) testing to assess the haemodynamic consequences of VT/VF and ensure a safe defibrillation threshold, but decided against this due to the absence of evidence to support EP testing in this situation and concern about potential adverse events. We elected empirically to program high zone boundaries, the longest programmable detection times, ATP as sole therapy within a single VT zone, and ATP before shocks in the VF zone.
Conclusions
Patients receiving LVAD support are at high risk of sustained ventricular arrhythmias but these may not cause sudden death. Whilst it is standard practice to reactivate a previously implanted ICD in an LVAD recipient, this should include discussion of the revised risks and benefits of ICD therapy following LVAD implantation. In particular, patients should be warned that they might receive a significant number of ICD shocks that may not be life saving. When ICDs are reactivated, device programming should minimize the risk of repeated shocks for non-sustained or well-tolerated ventricular arrhythmias. Implantation of a primary prevention ICD after implantation of an LVAD is not supported by current evidence, poses potential risks, and should be the subject of a clinical trial before it becomes standard practice.
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